Last reviewed · How we verify
Sodium Chloride 0.9% Inj post-exposure
At a glance
| Generic name | Sodium Chloride 0.9% Inj post-exposure |
|---|---|
| Also known as | Normal saline |
| Sponsor | BioAegis Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers (PHASE2)
- Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: